Takeda and Millennium - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008, featuring the Takeda's acquisition of Millenium Pharmaceuticals.Who: Takeda
With: Millennium‎
What: $8.8B buyout

Summary: With an eye on expanding in the U.S. market--and capitalizing on the weak dollar--Japan's Takeda offered $8.8 billion for Millennium Pharmaceuticals in April. Takeda, which is facing patent expirations for Actos and Prevacid, picked up Millennium's cancer drug Velcade in the deal. The company hopes to turn Velcade into a global blockbuster. Millennium had more than a half billion dollars in revenue last year and also has a number of inflammation and cancer therapies in the pipeline, which addresses Takeda's interest in oncology.

Takeda and Millennium - Top 10 deals of 2008

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.